Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J's Mixed Phase III Data For Esketamine Highlight Challenges In Resistant Depression

Executive Summary

J&J released data from the first two Phase III trials testing esketamine in patients with treatment-resistant depression, but only one study met the primary efficacy endpoint.

Advertisement

Related Content

Janssen’s Esketamine Gets US FDA Panel Endorsement, But With Pricing, Access And Diversion Concerns
Janssen’s Esketamine: US FDA Panel To Weigh Efficacy, REMS Restrictions For Treatment-Resistant Depression
Allergan Thinks It’s Ready To Withstand Restasis Generics
Keeping Track: J&J Esketamine, Sanofi Caplacizumab Lead Off September Submissions; US FDA Says No To Nucala
J&J Seeks A Priority Review For Depression Drug Esketamine
Key Drug Launches To Plan For In 2019
ICER’s 2019 Agenda Includes CAR-T Therapy, Drugs For Depression, Arthritis, AMD
On Track To Approval, Alkermes Hopes ALKS-5461 Can Change Future Of Depression Therapy
How 2018 Will Affect The Depression Market
Will J&J TRANSFORM Esketamine Into A Viable Depression Treatment?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel